GT201000095A - Producto de dispersión sólida que contiene un compuesto a base de n-aril urea - Google Patents
Producto de dispersión sólida que contiene un compuesto a base de n-aril ureaInfo
- Publication number
- GT201000095A GT201000095A GT201000095A GT201000095A GT201000095A GT 201000095 A GT201000095 A GT 201000095A GT 201000095 A GT201000095 A GT 201000095A GT 201000095 A GT201000095 A GT 201000095A GT 201000095 A GT201000095 A GT 201000095A
- Authority
- GT
- Guatemala
- Prior art keywords
- aril
- urea
- solid dispersion
- based compound
- product containing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
Abstract
LA PRESENTE INVENCIÓN SE REFIERE A UN PRODUCTO QUE COMPRENDE AL MENOS UN AGENTE FARMACÉUTICAMENTE ACTIVO A BASE DE N-ARIL UREA O UN AGENTE DE ESTRUCTURA RELACIONADA QUE ES OBTENIDO MEDIANTE A) LA PREPARACIÓN DE UNA MEZCLA LÍQUIDA QUE CONTIENE AL MENOS UN AGENTE ACTIVO, UN AGENTE FORMADOR DE MATRIZ ACEPTABLE PARA USO FARMACÉUTICO Y B) LA ELIMINACIÓN DEL O DE LOS SOLVENTES DE LA MEZCLA LÍQUIDA PARA OBTENER EL PRODUCTO DE DISPERSIÓN SÓLIDA.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US99961307P | 2007-10-19 | 2007-10-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
GT201000095A true GT201000095A (es) | 2012-04-03 |
Family
ID=40089072
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GT201000095A GT201000095A (es) | 2007-10-19 | 2010-04-15 | Producto de dispersión sólida que contiene un compuesto a base de n-aril urea |
Country Status (23)
Country | Link |
---|---|
US (1) | US20090143423A1 (es) |
EP (1) | EP2197426A2 (es) |
JP (1) | JP2011500647A (es) |
KR (1) | KR20100090689A (es) |
CN (1) | CN101827585A (es) |
AR (1) | AR068916A1 (es) |
AU (1) | AU2008313620A1 (es) |
BR (1) | BRPI0818339A2 (es) |
CA (1) | CA2699335A1 (es) |
CL (1) | CL2008003092A1 (es) |
CO (1) | CO6270303A2 (es) |
CR (1) | CR11441A (es) |
DO (1) | DOP2010000114A (es) |
EC (1) | ECSP10010184A (es) |
GT (1) | GT201000095A (es) |
MX (1) | MX2010004292A (es) |
PE (1) | PE20091041A1 (es) |
RU (1) | RU2010119924A (es) |
TW (1) | TW200922549A (es) |
UA (1) | UA100866C2 (es) |
UY (1) | UY31406A1 (es) |
WO (1) | WO2009050289A2 (es) |
ZA (1) | ZA201002130B (es) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2012505907A (ja) * | 2008-10-17 | 2012-03-08 | アボット・ラボラトリーズ | Trpv1拮抗薬 |
WO2010045402A1 (en) * | 2008-10-17 | 2010-04-22 | Abbott Laboratories | Trpv1 antagonists |
US20100210682A1 (en) * | 2009-02-19 | 2010-08-19 | Abbott Laboratories | Repeated Dosing of TRPV1 Antagonists |
EP2477593A1 (de) * | 2009-09-18 | 2012-07-25 | Basf Se | Verfahren zur herstellung von zubereitungen von in wasser schwer löslichen substanzen |
WO2012085236A1 (en) * | 2010-12-23 | 2012-06-28 | Abbott Gmbh & Co. Kg | Solid retard formulations based on solid dispersions |
JP2014505054A (ja) * | 2011-01-10 | 2014-02-27 | セルジーン コーポレイション | シクロプロパンカルボン酸{2−[(1s)−1−(3−エトキシ−4−メトキシ−フェニル)−2−メタンスルホニル−エチル]−3−オキソ−2,3−ジヒドロ−1h−イソインドール−4−イル}−アミドの経口剤形 |
US9034832B2 (en) | 2011-12-29 | 2015-05-19 | Abbvie Inc. | Solid compositions |
US20130172239A1 (en) * | 2011-12-29 | 2013-07-04 | Abbvie Inc. | Solid compositions |
TW201431570A (zh) | 2012-11-22 | 2014-08-16 | Ucb Pharma Gmbh | 用於經皮投服羅替戈汀(Rotigotine)之多天式貼片 |
WO2014120981A1 (en) | 2013-01-31 | 2014-08-07 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
WO2014151575A1 (en) | 2013-03-15 | 2014-09-25 | Boehringer Ingelheim International Gmbh | Solid oral dosage formulation of hcv inhibitor in the amorphous state |
US10046151B2 (en) | 2013-07-03 | 2018-08-14 | Lts Lohmann Therapie-Systeme, Ag | Transdermal therapeutic system with electronic component |
NZ716840A (en) | 2013-08-27 | 2017-06-30 | Gilead Pharmasset Llc | Combination formulation of two antiviral compounds |
US11752110B2 (en) | 2014-05-20 | 2023-09-12 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system including an interface mediator |
WO2015177204A1 (en) | 2014-05-20 | 2015-11-26 | Lts Lohmann Therapie-Systeme Ag | Transdermal delivery system containing rotigotine |
WO2015177209A1 (en) | 2014-05-20 | 2015-11-26 | Lts Lohmann Therapie-Systeme Ag | Method for adjusting the release of active agent in a transdermal delivery system |
US20190008865A1 (en) * | 2015-12-22 | 2019-01-10 | Arizona Board Of Regents On Behalf Of The University Of Arizona | Compositions and methods for treatment, amelioration, and prevention of anesthesia-induced hypothermia |
JP7425794B2 (ja) * | 2018-10-30 | 2024-01-31 | ペロトン セラピューティクス, インコーポレイテッド | 置換されたインダンを含む固体分散体及び医薬組成物並びにそれの製造方法及び使用 |
WO2021039023A1 (ja) | 2019-08-23 | 2021-03-04 | 持田製薬株式会社 | ヘテロシクリデンアセトアミド誘導体の製造方法 |
EP4019485A4 (en) | 2019-08-23 | 2022-10-26 | Mochida Pharmaceutical Co., Ltd. | METHOD FOR THE PRODUCTION OF HETEROCYCLIDENE ACETAMIDE DERIVATIVES |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5362878A (en) * | 1991-03-21 | 1994-11-08 | Pfizer Inc. | Intermediates for making N-aryl and N-heteroarylamide and urea derivatives as inhibitors of acyl coenzyme A: cholesterol acyl transferase (ACAT) |
AU4028393A (en) * | 1992-05-28 | 1993-12-30 | Pfizer Inc. | New (N)-aryl and (N)-heteroarylurea derivatives as inhibitors of acyl coenzyme a:cholesterol acyl transferase (ACAT) |
EP1015046A2 (en) * | 1998-07-14 | 2000-07-05 | Em Industries, Inc. | Microdisperse drug delivery systems |
US7015233B2 (en) * | 2003-06-12 | 2006-03-21 | Abbott Laboratories | Fused compounds that inhibit vanilloid subtype 1 (VR1) receptor |
CN102512372A (zh) * | 2004-06-08 | 2012-06-27 | 沃泰克斯药物股份有限公司 | 药物组合物 |
DE602005007048D1 (de) * | 2004-08-27 | 2008-07-03 | Bayer Pharmaceuticals Corp | Pharmazeutische zusammensetzungen in form fester dispersionen zur behandlung von krebs |
EP1877042A4 (en) * | 2005-04-18 | 2011-03-02 | Rubicon Res Private Ltd | BIOLOGICALLY IMPROVED COMPOSITIONS |
KR100715355B1 (ko) * | 2005-09-30 | 2007-05-07 | 주식회사유한양행 | 프란루카스트를 함유하는 분무-건조 과립 및 그의 제조방법 |
CN101346128B (zh) * | 2005-10-25 | 2013-10-02 | 雅培制药有限公司 | 包含低水溶解度药物的配方及其使用方法 |
WO2007066189A2 (en) * | 2005-12-09 | 2007-06-14 | Pfizer Products Inc. | Salts, prodrugs and formulations of 1-[5-(4-amino-7-isopropyl-7h-pyrrolo[2,3-d]pyrimidine-5-carbonyl)-2-methoxy-phenyl]-3-(2,4-dichloro-phenyl)-urea |
US7745448B2 (en) * | 2005-12-28 | 2010-06-29 | Abbott Laboratories Inc. | Crystalline N-(4-(4-aminothieno[2,3-d]pyrimidin-5-yl)phenyl)-N′-(2-fluoro-5-(trifluoromethyl)phenyl)urea ethanolate |
KR101418267B1 (ko) * | 2006-02-09 | 2014-07-11 | 머크 샤프 앤드 돔 코포레이션 | Cetp 억제제의 중합체 제형 |
-
2008
- 2008-10-17 US US12/253,499 patent/US20090143423A1/en not_active Abandoned
- 2008-10-17 CL CL2008003092A patent/CL2008003092A1/es unknown
- 2008-10-17 CA CA2699335A patent/CA2699335A1/en not_active Abandoned
- 2008-10-17 WO PCT/EP2008/064073 patent/WO2009050289A2/en active Application Filing
- 2008-10-17 PE PE2008001785A patent/PE20091041A1/es not_active Application Discontinuation
- 2008-10-17 BR BRPI0818339 patent/BRPI0818339A2/pt not_active IP Right Cessation
- 2008-10-17 RU RU2010119924/15A patent/RU2010119924A/ru not_active Application Discontinuation
- 2008-10-17 EP EP08840773A patent/EP2197426A2/en not_active Withdrawn
- 2008-10-17 UA UAA201006030A patent/UA100866C2/ru unknown
- 2008-10-17 AR ARP080104542A patent/AR068916A1/es not_active Application Discontinuation
- 2008-10-17 JP JP2010529406A patent/JP2011500647A/ja active Pending
- 2008-10-17 UY UY31406A patent/UY31406A1/es not_active Application Discontinuation
- 2008-10-17 TW TW097140229A patent/TW200922549A/zh unknown
- 2008-10-17 MX MX2010004292A patent/MX2010004292A/es not_active Application Discontinuation
- 2008-10-17 CN CN200880112161A patent/CN101827585A/zh active Pending
- 2008-10-17 KR KR1020107010874A patent/KR20100090689A/ko not_active Application Discontinuation
- 2008-10-17 AU AU2008313620A patent/AU2008313620A1/en not_active Abandoned
-
2010
- 2010-03-25 ZA ZA2010/02130A patent/ZA201002130B/en unknown
- 2010-04-15 GT GT201000095A patent/GT201000095A/es unknown
- 2010-04-16 DO DO2010000114A patent/DOP2010000114A/es unknown
- 2010-04-27 CO CO10049270A patent/CO6270303A2/es not_active Application Discontinuation
- 2010-05-17 EC EC2010010184A patent/ECSP10010184A/es unknown
- 2010-05-19 CR CR11441A patent/CR11441A/es not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
WO2009050289A2 (en) | 2009-04-23 |
CA2699335A1 (en) | 2009-04-23 |
RU2010119924A (ru) | 2011-11-27 |
AR068916A1 (es) | 2009-12-16 |
US20090143423A1 (en) | 2009-06-04 |
JP2011500647A (ja) | 2011-01-06 |
BRPI0818339A2 (pt) | 2015-04-22 |
CN101827585A (zh) | 2010-09-08 |
ECSP10010184A (es) | 2010-06-29 |
WO2009050289A3 (en) | 2010-03-25 |
CR11441A (es) | 2010-10-25 |
MX2010004292A (es) | 2010-08-02 |
UA100866C2 (ru) | 2013-02-11 |
DOP2010000114A (es) | 2010-05-15 |
EP2197426A2 (en) | 2010-06-23 |
KR20100090689A (ko) | 2010-08-16 |
CO6270303A2 (es) | 2011-04-20 |
CL2008003092A1 (es) | 2009-11-27 |
ZA201002130B (en) | 2011-11-30 |
UY31406A1 (es) | 2009-05-29 |
PE20091041A1 (es) | 2009-08-22 |
TW200922549A (en) | 2009-06-01 |
AU2008313620A1 (en) | 2009-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
GT201000095A (es) | Producto de dispersión sólida que contiene un compuesto a base de n-aril urea | |
ECSP20070854A (es) | Compuestos heteroaril tetracíclicos | |
CL2017003436A1 (es) | Compuestos de benzoxacepina oxazolidinona y métodos de uso | |
AR051969A1 (es) | Metodos y composiciones que usan compuestos inmunomoduladores para el tratamiento y el manejo de lesiones del sistema nervioso central | |
UY29701A1 (es) | Formulaciones líquidas para la administración controlada de derivados de bencisoxazol | |
DOP2010000259A (es) | Derivados heterociclicos de urea y metodos de uso de los mismos-211 | |
WO2010041141A3 (en) | Oil-based foamable carriers and formulations | |
UY30107A1 (es) | Nuevos derivados de pirimidina, composiciones farmaceuticas conteniendolos, procesos de preparacion y aplicaciones | |
CU20060153A7 (es) | Nueva forma cristalina v de agomelatina, procedimiento para su preparación y composiciones farmacéuticas que las contienen | |
BR112015018087A8 (pt) | composto, composição farmacêutica e uso | |
AR059350A1 (es) | Formulacion farmaceutica para aerosoles con dos o mas principios activos y al menos una sustancia tensioactiva | |
PA8800101A1 (es) | Producto de dispersion sólida que contiene un compuesto a base de n-aril urea | |
CL2015001652A1 (es) | Compuestos derivados de 4-(bifenil-3-il)-7h-imidazo[4,5-c]piridazina, moduladores de la actividad del receptor gabaa; composicion farmaceutica que los comprende; combinacion que los comprende junto a un segundo agente farmaceuticamente activo; metodo de tratamiento del dolor; y su uso para el tratamiento del dolor. | |
ES2484721T3 (es) | Mezcla fluidizante para composición hidráulica | |
UY35298A (es) | Formulación en dispersión sólida de un compuesto antiviral | |
CL2007003356A1 (es) | Compuestos derivados de benzopirazoles; proceso para la preparacion de dichos compuestos; composicion farmaceutica que comprende a dichos compuestos y otro agente activo; y su uso para el tratamiento del asma, inflamacion, entre otras enfermedades. | |
CL2008002247A1 (es) | Compuestos derivados de fenil amida; proceso de preparacion; composicion farmaceutica que los contiene; y su uso en la preparacion de medicamentos para el tratamiento de trastornos del sueno, narcolepsia y trastornos psiquiatricos, entre otros. | |
PE20090607A1 (es) | Formulacion farmaceutica de dispersion liposomal en polvo seco | |
CL2013000488A1 (es) | Co-cristales de compuestos derivados de (2r)-5-oxo-1-(bencilpiperidin-4-il)-n-(piridin-2-il)pirrolidin-2-carboxamida y un agente de formacion de co-cristales; sales de los compuestos; compuestos intermediarios; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias e infecciosas. | |
DOP2010000374A (es) | Derivados heterociclicos de la urea y sus metodos de empleo | |
UY31864A (es) | Derivados de urea hetericíclica y métodos de uso de los mismos-332 | |
CO6351721A2 (es) | Uso de dronedarona para la preparacion de un medicamento para la prevencion de ictus o ataque isquemico transitorio | |
UY29561A1 (es) | Derivados de quinazolina, composiciones farmacéuticas que los contienen, procedimientos de preparación y aplicaciones | |
CL2011001207A1 (es) | Extruidos que contienen al menos una sustancia farmacéuticamente activa en forma de agujas, tal que la relación entre el tamaño de partículas de la sustancia farmacéuticamente activa con forma de agujas y el diámetro de la cadena es de al menos 1:20; composición farmacéutica; y su uso para preparar medicamentos. | |
AR086491A1 (es) | Composicion farmaceutica que comprende fexofenadina |